Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar i depression

International Journal of Neuropsychopharmacology

Volumn 12, Issue 6, 2009, Pages 773-782

  Brown, Eileen ^a   Dunner, David L ^b   McElroy, Susan L ^c   Keck, Paul E ^c,d   Adams, David H ^a   Degenhardt, Elisabeth ^a   Tohen, Mauricio ^a,e   Houston, John P ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MCLEAN HOSPITAL   (United States)

Author keywords

Antipsychotic; Bipolar depression; Clinical trial; Mania; Response

Indexed keywords

BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; CHOLESTEROL; FLUOXETINE PLUS OLANZAPINE; HYPNOTIC AGENT; LAMOTRIGINE; LORAZEPAM; CALCIUM CHANNEL BLOCKING AGENT; FLUOXETINE; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR; TRIAZINE DERIVATIVE;

ADULT; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; ATTENTION DISTURBANCE; BACKACHE; BIPOLAR DEPRESSION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REMISSION; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; WEIGHT GAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE; ADOLESCENT; BIPOLAR DISORDER; DOSE RESPONSE; DRUG COMBINATION; HOSPITALIZATION; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TIME;

ADOLESCENT; ADULT; BENZODIAZEPINES; BIPOLAR DISORDER; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 68849103782     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145708009735     Document Type: Article

References (22)

1. APA (2002). Practice guideline for the treatment of patients with bipolar disorder (2nd edn). American Journal of Psychiatry 159 (Suppl.), 1-50.
2. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, DeVeaugh-Geiss J, Lamictal 606 Study Group (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Archives of General Psychiatry 60, 392-400.
3. Brown E, McElroy SL, Keck Jr. P.E., Deldar A, Adams DH, Tohen M, Williamson DJ (2006). A seven-week comparison of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Journal of Clinical Psychiatry 67, 1025-1033.
4. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, Montgomery P, Ascher J, Paska W, Earl N, DeVeaugh-Geiss J, Lamictal 605 Study Group (2003). A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 64, 1013-1024.
5. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry 60, 79-88.
6. Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, Monaghan ET, Leadbetter RA (2008). Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo controlled clinical trials. Bipolar Disorders 10, 323-333.
7. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V (2002). Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. Journal of Clinical Psychiatry 63, 1012-1019.
8. Corya SA, Andersen SW, Detke HC, Kelly LS, Van Campen LE, Sanger TM, Williamson DJ, Dubé S (2003). Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study. Journal of Clinical Psychiatry 64, 1349-1356.
9. Crawford AM, Beasley Jr. C.M., Tollefson GD (1997). The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research 26, 41-54.
10. Derogatis LR, Spencer MS (1982). The Brief Symptom Inventory (BSI): Administration, Procedure, and Scoring Manual. Baltimore, MD: Johns Hopkins University School of Medicine, Clinical Psychometrics Research Unit.
11. Expert Panel on Detection, valuation, and Treatment of High Blood Cholesterol in Adults (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association 285, 2486-2497.
12. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM (2000). A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology 20, 607-614.
13. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, revised edn. Bethesda, MD: Department of Health, Education, and Welfare.
14. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA, Coryell W, Maser JD, Keller MB (2005). Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Archives of General Psychiatry 62, 1322-1330.
15. Keck Jr. P.E., Corya SA, Altshuler LL, Ketter TA, McElroy SL, Case M, Briggs SD, Tohen M (2005). Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. Journal of Clinical Psychiatry 66, 611-616.
16. Keck Jr. P.E., Nelson EB, McElroy SL (2003). Advances in the pharmacologic treatment of bipolar depression. Biological Psychiatry 53, 671-679.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
18. Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, Rush AJ, Keck Jr. P.E., McElroy SL, Luckenbaugh DA, et al. (2003). Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. Journal of Clinical Psychiatry 64, 680-690.
19. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, Crismon ML, Ketter TA, Sachs GS, Swann AC, Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder (2005). The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Journal of Clinical Psychiatry 66, 870-886.
20. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, et al. (2003). Efficacy of olanzapine and olanzapine/fluoxetine combination in the treatment of bipolar I depression. Archives of General Psychiatry 60, 1079-1088.
21. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, Sharma V, Silverstone P, Alda M, Baruch P, et al., Canadian Network for Mood and Anxiety Treatments (2005). Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorders 7 (Suppl. 3), 5-69.
22. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity, and sensitivity. British Journal of Psychiatry 133, 429-435.